Hims & Hers Enters Testosterone Market: A Game Changer?

Hims & Hers stock surges as they enter the $20 million testosterone replacement market! Find out how their new men's health category, featuring compounded enclomiphene and a future exclusive deal for FDA-approved KYZATREX, aims to boost growth beyond weight-loss drugs. We'll cover the investor optimism, analyst ratings, and the stock's wild volatility, plus explore if this move can help Hims & Hers reach new heights after a year of impressive gains. Hosted on Acast. See acast.com/privacy for more information.